Do analysts recommend TSTL or NIOX?

NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 32.63%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts clearly believe NIOX Group is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NIOX Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, TSTL or NIOX?

NIOX Group has lower revenue, but higher earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tristel £49.54M 4.07 £6.54M £16.24 25.86 NIOX Group £48.70M 5.60 £995.88M £1.64 39.54

Is TSTL or NIOX more profitable?

Tristel has a net margin of 15.88% compared to NIOX Group's net margin of 14.37%. Tristel's return on equity of 23.64% beat NIOX Group's return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.88% 23.64% 9.89% NIOX Group 14.37% 10.14% 3.95%

Do analysts recommend EKF or TSTL?

EKF Diagnostics presently has a consensus price target of GBX 35, suggesting a potential upside of 38.34%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe EKF Diagnostics is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is EKF or TSTL more profitable?

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.12%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets EKF Diagnostics 4.12% 3.01% 5.27% Tristel 15.88% 23.64% 9.89%

Do analysts prefer SPEC or TSTL?

INSPECS Group currently has a consensus price target of GBX 60, indicating a potential downside of 36.17%. Given INSPECS Group's stronger consensus rating and higher probable upside, equities analysts plainly believe INSPECS Group is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INSPECS Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SPEC or TSTL more profitable?

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity. Company Net Margins Return on Equity Return on Assets INSPECS Group -2.67% -6.07% 0.45% Tristel 15.88% 23.64% 9.89%

Which has better earnings and valuation, CREO or TSTL?

Tristel has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Creo Medical Group £6M 10.04 -£25.04M £1.00 12.40 Tristel £49.54M 4.07 £6.54M £16.24 25.86

Tristel (TSTL) Competitors

GBX 420 +10.00 (+2.44%)

As of 08/14/2026 12:20 PM Eastern

Compare

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

Should you buy Tristel stock or one of its competitors? Tristel's main competitors and comparable companies include Advanced Medical Solutions Group (AMS), NIOX Group (NIOX), EKF Diagnostics (EKF), INSPECS Group (SPEC), and Creo Medical Group (CREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Tristel compare to Advanced Medical Solutions Group?

Tristel (LON:TSTL) and Advanced Medical Solutions Group (LON:AMS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	4.07	£6.54M	£16.24	25.86
Advanced Medical Solutions Group	£228.94M	2.67	£11.22M	£4.52	62.06

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.4%. Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.0%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend.

Tristel has a net margin of 15.88% compared to Advanced Medical Solutions Group's net margin of 4.35%. Tristel's return on equity of 23.64% beat Advanced Medical Solutions Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
Advanced Medical Solutions Group	4.35%	3.87%	2.35%

Tristel has a beta of 0.346, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.704, suggesting that its share price is 30% less volatile than the broader market.

22.5% of Tristel shares are held by institutional investors. Comparatively, 22.7% of Advanced Medical Solutions Group shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Comparatively, 4.0% of Advanced Medical Solutions Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Advanced Medical Solutions Group has a consensus target price of GBX 270.25, indicating a potential downside of 3.65%. Given Advanced Medical Solutions Group's stronger consensus rating and higher probable upside, analysts plainly believe Advanced Medical Solutions Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Advanced Medical Solutions Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Advanced Medical Solutions Group had 3 more articles in the media than Tristel. MarketBeat recorded 3 mentions for Advanced Medical Solutions Group and 0 mentions for Tristel. Advanced Medical Solutions Group's average media sentiment score of 0.74 beat Tristel's score of 0.00 indicating that Advanced Medical Solutions Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Tristel	Neutral
Advanced Medical Solutions Group	Positive

Summary

Advanced Medical Solutions Group beats Tristel on 11 of the 18 factors compared between the two stocks.

How does Tristel compare to NIOX Group?

Tristel (LON:TSTL) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

22.5% of Tristel shares are owned by institutional investors. Comparatively, 7.6% of NIOX Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 5.1% of NIOX Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Tristel's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company	Overall Sentiment
Tristel	Neutral
NIOX Group	Neutral

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.4%. NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.9%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Tristel has a beta of 0.346, suggesting that its share price is 65% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 32.63%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts clearly believe NIOX Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Tristel has a net margin of 15.88% compared to NIOX Group's net margin of 14.37%. Tristel's return on equity of 23.64% beat NIOX Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
NIOX Group	14.37%	10.14%	3.95%

NIOX Group has lower revenue, but higher earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	4.07	£6.54M	£16.24	25.86
NIOX Group	£48.70M	5.60	£995.88M	£1.64	39.54

Summary

Tristel and NIOX Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Tristel compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

EKF Diagnostics presently has a consensus price target of GBX 35, suggesting a potential upside of 38.34%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe EKF Diagnostics is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.12%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
Tristel	15.88%	23.64%	9.89%

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 22.5% of Tristel shares are owned by institutional investors. 40.0% of EKF Diagnostics shares are owned by company insiders. Comparatively, 21.0% of Tristel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tristel has lower revenue, but higher earnings than EKF Diagnostics. Tristel is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.11	£4.68M	£0.47	53.83
Tristel	£49.54M	4.07	£6.54M	£16.24	25.86

In the previous week, EKF Diagnostics had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Tristel. EKF Diagnostics' average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
Tristel	Neutral

EKF Diagnostics has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Tristel has a beta of 0.346, meaning that its stock price is 65% less volatile than the broader market.

Summary

EKF Diagnostics beats Tristel on 8 of the 15 factors compared between the two stocks.

How does Tristel compare to INSPECS Group?

INSPECS Group (LON:SPEC) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

INSPECS Group has a beta of 1.607, meaning that its share price is 61% more volatile than the broader market. Comparatively, Tristel has a beta of 0.346, meaning that its share price is 65% less volatile than the broader market.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
INSPECS Group	Neutral
Tristel	Neutral

INSPECS Group currently has a consensus price target of GBX 60, indicating a potential downside of 36.17%. Given INSPECS Group's stronger consensus rating and higher probable upside, equities analysts plainly believe INSPECS Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.7% of INSPECS Group shares are held by institutional investors. Comparatively, 22.5% of Tristel shares are held by institutional investors. 19.6% of INSPECS Group shares are held by company insiders. Comparatively, 21.0% of Tristel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INSPECS Group	-2.67%	-6.07%	0.45%
Tristel	15.88%	23.64%	9.89%

Tristel has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSPECS Group	£191.70M	0.54	-£4.11M	-£9.40	N/A
Tristel	£49.54M	4.07	£6.54M	£16.24	25.86

Summary

Tristel beats INSPECS Group on 9 of the 14 factors compared between the two stocks.

How does Tristel compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Creo Medical Group has a beta of 1.563854, indicating that its share price is 56% more volatile than the broader market. Comparatively, Tristel has a beta of 0.346, indicating that its share price is 65% less volatile than the broader market.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 22.5% of Tristel shares are held by institutional investors. 7.0% of Creo Medical Group shares are held by company insiders. Comparatively, 21.0% of Tristel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Creo Medical Group has a net margin of 88.33% compared to Tristel's net margin of 15.88%. Tristel's return on equity of 23.64% beat Creo Medical Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creo Medical Group	88.33%	9.56%	-20.09%
Tristel	15.88%	23.64%	9.89%

Tristel has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creo Medical Group	£6M	10.04	-£25.04M	£1.00	12.40
Tristel	£49.54M	4.07	£6.54M	£16.24	25.86

In the previous week, Creo Medical Group's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
Creo Medical Group	Neutral
Tristel	Neutral

Summary

Tristel beats Creo Medical Group on 7 of the 11 factors compared between the two stocks.

Get Tristel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSTL vs. The Competition

Export

Metric	Tristel	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£201.59M	£5.88B	£7.03B	£2.88B
Dividend Yield	3.46%	1.76%	2.57%	6.11%
P/E Ratio	25.86	26.22	268.81	368.68
Price / Sales	4.07	63.23	574.46	83,339.32
Price / Cash	20.96	33.92	70.48	27.89
Price / Book	6.15	6.10	12.91	7.18
Net Income	£6.54M	£148.67M	£3.45B	£5.89B
7 Day Performance	2.44%	1.89%	1.11%	0.91%
1 Month Performance	10.53%	4.04%	1.33%	2.94%
1 Year Performance	17.76%	9.25%	62.44%	64.32%

Tristel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSTL Tristel	N/A	GBX 420 +2.4%	N/A	+16.7%	£201.59M	£49.54M	25.86	208	Gap Up
AMS Advanced Medical Solutions Group	1.0832 of 5 stars	GBX 281 -0.2%	GBX 270.25 -3.8%	+36.5%	£611.45M	£228.94M	62.17	10	News Coverage High Trading Volume
NIOX NIOX Group	2.5337 of 5 stars	GBX 68.56 +3.9%	GBX 86 +25.4%	-3.2%	£288.55M	£48.70M	41.80	92	Gap Up
EKF EKF Diagnostics	1.9875 of 5 stars	GBX 25.50 +0.8%	GBX 35 +37.3%	-10.0%	£109.64M	£51.56M	54.26	356
SPEC INSPECS Group	0.473 of 5 stars	GBX 94 -3.1%	GBX 60 -36.2%	+103.9%	£102.62M	£191.70M	N/A	1,673	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:TSTL) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tristel (TSTL) Competitors

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

How does Tristel compare to Advanced Medical Solutions Group?

Summary

How does Tristel compare to NIOX Group?

Summary

How does Tristel compare to EKF Diagnostics?

Summary

How does Tristel compare to INSPECS Group?

Summary

How does Tristel compare to Creo Medical Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSTL vs. The Competition

Tristel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tristel (TSTL) Competitors

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

How does Tristel compare to Advanced Medical Solutions Group?

Which has stronger valuation & earnings, TSTL or AMS?

Is TSTL or AMS a better dividend stock?

Is TSTL or AMS more profitable?

Which has more volatility & risk, TSTL or AMS?

Do institutionals & insiders have more ownership in TSTL or AMS?

Do analysts prefer TSTL or AMS?

Does the media refer more to TSTL or AMS?

Summary

How does Tristel compare to NIOX Group?

Do insiders and institutionals believe in TSTL or NIOX?

Does the media refer more to TSTL or NIOX?

Is TSTL or NIOX a better dividend stock?

Which has more volatility & risk, TSTL or NIOX?

Do analysts recommend TSTL or NIOX?

Is TSTL or NIOX more profitable?

Which has stronger earnings & valuation, TSTL or NIOX?

Summary

How does Tristel compare to EKF Diagnostics?

Do analysts recommend EKF or TSTL?

Is EKF or TSTL more profitable?

Do institutionals and insiders hold more shares of EKF or TSTL?

Which has preferable earnings & valuation, EKF or TSTL?

Does the media favor EKF or TSTL?

Which has more volatility & risk, EKF or TSTL?

Summary

How does Tristel compare to INSPECS Group?

Which has more risk & volatility, SPEC or TSTL?

Does the media favor SPEC or TSTL?

Do analysts prefer SPEC or TSTL?

Do institutionals & insiders have more ownership in SPEC or TSTL?

Is SPEC or TSTL more profitable?

Which has better valuation and earnings, SPEC or TSTL?

Summary

How does Tristel compare to Creo Medical Group?

Which has more risk and volatility, CREO or TSTL?

Do insiders and institutionals have more ownership in CREO or TSTL?

Is CREO or TSTL more profitable?

Which has better earnings and valuation, CREO or TSTL?

Does the media refer more to CREO or TSTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSTL vs. The Competition

Tristel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools